FURVENT Misses Its Central Review Endpoint
ArriVent and its Chinese development partner Allist reported that first-line firmonertinib monotherapy did not meet the blinded independent central review progression-free-survival endpoint in the global Phase 3 FURVENT study of EGFR exon 20 insertion…
